132 related articles for article (PubMed ID: 38515461)
1. Integrating single-cell and bulk sequencing data to identify glycosylation-based genes in non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Zhou Z; Gao Y; Deng L; Lu X; Lai Y; Wu J; Chen S; Li C; Liang H
PeerJ; 2024; 12():e17002. PubMed ID: 38515461
[TBL] [Abstract][Full Text] [Related]
2. Integrative genomic signatures of hepatocellular carcinoma derived from nonalcoholic Fatty liver disease.
Frades I; Andreasson E; Mato JM; Alexandersson E; Matthiesen R; MartÃnez-Chantar ML
PLoS One; 2015; 10(5):e0124544. PubMed ID: 25993042
[TBL] [Abstract][Full Text] [Related]
3. Identification of Glucose Metabolism-Related Genes in the Progression from Nonalcoholic Fatty Liver Disease to Hepatocellular Carcinoma.
Wang S; Li Y; Liu N; Shen W; Xu W; Yao P
Genet Res (Camb); 2022; 2022():8566342. PubMed ID: 36407083
[TBL] [Abstract][Full Text] [Related]
4. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
5. Elevated levels of circulating ITIH4 are associated with hepatocellular carcinoma with nonalcoholic fatty liver disease: from pig model to human study.
Nakamura N; Hatano E; Iguchi K; Sato M; Kawaguchi H; Ohtsu I; Sakurai T; Aizawa N; Iijima H; Nishiguchi S; Tomono T; Okuda Y; Wada S; Seo S; Taura K; Uemoto S; Ikegawa M
BMC Cancer; 2019 Jun; 19(1):621. PubMed ID: 31238892
[TBL] [Abstract][Full Text] [Related]
6. Circadian dysfunction induces NAFLD-related human liver cancer in a mouse model.
Padilla J; Osman NM; Bissig-Choisat B; Grimm SL; Qin X; Major AM; Yang L; Lopez-Terrada D; Coarfa C; Li F; Bissig KD; Moore DD; Fu L
J Hepatol; 2024 Feb; 80(2):282-292. PubMed ID: 37890720
[TBL] [Abstract][Full Text] [Related]
7. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish.
de Oliveira S; Houseright RA; Graves AL; Golenberg N; Korte BG; Miskolci V; Huttenlocher A
J Hepatol; 2019 Apr; 70(4):710-721. PubMed ID: 30572006
[TBL] [Abstract][Full Text] [Related]
8. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.
Fujiwara N; Kubota N; Crouchet E; Koneru B; Marquez CA; Jajoriya AK; Panda G; Qian T; Zhu S; Goossens N; Wang X; Liang S; Zhong Z; Lewis S; Taouli B; Schwartz ME; Fiel MI; Singal AG; Marrero JA; Fobar AJ; Parikh ND; Raman I; Li QZ; Taguri M; Ono A; Aikata H; Nakahara T; Nakagawa H; Matsushita Y; Tateishi R; Koike K; Kobayashi M; Higashi T; Nakagawa S; Yamashita YI; Beppu T; Baba H; Kumada H; Chayama K; Baumert TF; Hoshida Y
Sci Transl Med; 2022 Jun; 14(650):eabo4474. PubMed ID: 35731891
[TBL] [Abstract][Full Text] [Related]
9. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma.
Liu YL; Patman GL; Leathart JB; Piguet AC; Burt AD; Dufour JF; Day CP; Daly AK; Reeves HL; Anstee QM
J Hepatol; 2014 Jul; 61(1):75-81. PubMed ID: 24607626
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
11. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
[TBL] [Abstract][Full Text] [Related]
12. Estrogen-related genes influence immune cell infiltration and immunotherapy response in Hepatocellular Carcinoma.
Gao B; Wang Y; Li C; Lu S
Front Immunol; 2023; 14():1114717. PubMed ID: 36814910
[TBL] [Abstract][Full Text] [Related]
13. Predicting Non-Alcoholic Fatty Liver Disease Progression and Immune Deregulations by Specific Gene Expression Patterns.
Zeng F; Zhang Y; Han X; Zeng M; Gao Y; Weng J
Front Immunol; 2020; 11():609900. PubMed ID: 33574818
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential feature genes in non-alcoholic fatty liver disease using bioinformatics analysis and machine learning strategies.
Zhang Z; Wang S; Zhu Z; Nie B
Comput Biol Med; 2023 May; 157():106724. PubMed ID: 36898287
[TBL] [Abstract][Full Text] [Related]
15. Identification of genes in hepatocellular carcinoma induced by non-alcoholic fatty liver disease.
Cai C; Song X; Yu C
Cancer Biomark; 2020; 29(1):69-78. PubMed ID: 32623384
[TBL] [Abstract][Full Text] [Related]
16. A three-gene signature reveals changes in the tumor immune microenvironment in the progression from NAFLD to HCC.
Liu L; Tang H; Wang K; Liu J; Luo N; Jin G
Sci Rep; 2023 Dec; 13(1):22295. PubMed ID: 38102321
[TBL] [Abstract][Full Text] [Related]
17. Glycosylation-related molecular subtypes and risk score of hepatocellular carcinoma: Novel insights to clinical decision-making.
Shi Y; Wang Y; Yang R; Zhang W; Zhang Y; Feng K; Lv Q; Niu K; Chen J; Li L; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1090324. PubMed ID: 36605944
[TBL] [Abstract][Full Text] [Related]
18. Defects in long-chain 3-hydroxy acyl-CoA dehydrogenase lead to hepatocellular carcinoma: A novel etiology of hepatocellular carcinoma.
Khare T; Khare S; Angdisen JJ; Zhang Q; Stuckel A; Mooney BP; Ridenhour SE; Gitan RS; Hammoud GM; Ibdah JA
Int J Cancer; 2020 Sep; 147(5):1461-1473. PubMed ID: 32115688
[TBL] [Abstract][Full Text] [Related]
19. Prognostic and immune roles of UROC1 in human cancers: from mechanism exploration of NAFLD and HCC to pan-cancer analysis.
Wang QY; Liu YJ; Hu Y; Xiao H; Xia LL; Wu YG
Eur Rev Med Pharmacol Sci; 2024 Jan; 28(2):622-644. PubMed ID: 38305606
[TBL] [Abstract][Full Text] [Related]
20. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
